Background
Methods
Patients
Type | N |
---|---|
Age (ys)
| |
CIN, | |
40.1 (20–80) | 216 |
Invasive cervical carcinoma, | |
50.1 (28–81) | 84 |
Histological type
| |
CIN grade I | 78 |
CIN grade II | 64 |
CIN grade III | 74 |
Invasive carcinoma | 84 |
Pathological stages
| |
Cancer in situ, stage 0 | 74 |
II | 50 |
III | 34 |
FIGO stages
| |
0 | 74 |
IA | 1 |
IB | 4 |
IIA | 14 |
IIB | 32 |
IIIA | 2 |
IIIB | 29 |
IVA | 1 |
IVB | 1 |
Study design
Treatment
Follow-up information
Immunohistochemical staining
Statistical analysis
Results
LI of TK1 and Ki-67
Type | Grade/stage | No | TK1 total* | P | TK1 cyto + nucl** | P | Ki-67 | P |
---|---|---|---|---|---|---|---|---|
CIN | Grade I | 78 | 17.5±16.7 | 7.3±11.2 | 10.8±13.0 | |||
<0.0001 | <0.0001 | <0.0001 | ||||||
Grade II | 64 | 37.2±22.9 | 22.1±18.7 | 26.5±21.2 | ||||
<0.0001 | <0.0001 | <0.0001 | ||||||
Carcinoma in situ
| Grade III | 74 | 54.6±20.5 | 36.6±18.9 | 43.9±23.1 | |||
(CIN III) | ||||||||
0.001 | 0.041 | <0.0001 | ||||||
Invasive CA | Stage II | 50 | 66.6±17.8 | 43.5±18.4 | 60.5±23.1 | |||
0.029 | 0.117 | 0.701 | ||||||
Stage III | 34 | 74.9±15.4 | 49.7±18.4 | 62.5±23.2 |
Intensity of TK1 and Ki-67 expression
Type | Grade/stage | Low | High | P |
---|---|---|---|---|
CIN | Grade I | 48 | 30 | |
0.024 | ||||
Grade II | 22 | 42 | ||
0.012 | ||||
Cancer in situ
| Grade III | 12 | 62 | |
0.026 | ||||
Invasive CA | Stage II | 2 | 48 | |
0.83 | ||||
Stage III | 1 | 33 |
Survival of patients in relation to pathologic and FIGO stages
TK1 and Ki-67 in relation to survival
Death of CIN III and invasive cervical carcinoma patients
Survival of CIN III and invasive cervical carcinoma patients
Survival of invasive cervical carcinoma patients
Log rank | Multivariate | |||||
---|---|---|---|---|---|---|
Variable | X2
| DF | P | Hazard risk | 95% CI | P |
CIN III + invasive CA (n=106)
| ||||||
"Total TK1" | 8.60 | 1 | 0.003 | 3.30 | 1.3 – 8.8 | 0.015 |
"Cyto+nucl TK1" | 11.39 | 1 | <0.001 | 4.30 | 1.7 – 10.9 | 0.002 |
Ki-67 | 4.13 | 1 | 0.042 | nd | nd | 0.541 |
Pathological stages: | ||||||
0 versus II | 12.51 | 1 | <0.001 | 6.53 | 1.35-31.38 | 0.020 |
0 versus III | 7.315 | 1 | 0,007 | nd | nd | 0.065 |
FIGO stages: | ||||||
0 versus IA-IIA | 13.23 | 1 | <0.001 | 9.19 | 1.68-50.35 | 0.011 |
0 versus IIB-IV | 9.47 | 1 | 0.002 | nd | nd | 0.060 |
Age | 0.25 | 1 | 0.873 | nd | nd | 0.160 |
Invasive CA (n=61)
| ||||||
"Total TK1" | 3.51 | 1 | 0,061 | nd | nd | 0.060 |
"Cyto+nucl TK1" | 6.59 | 1 | 0,01 | 7.19 | 1.7– 29.7 | 0.015 |
Ki-67 | 0.00 | 1 | 0.999 | nd | nd | 0.468 |
FIGO stages IA+IIA versus IIB+IV | 0.44 | 1 | 0.509 | nd | nd | 0.889 |
Pathological stage II versus III | 0.91 | 1 | 0.329 | nd | nd | 0.280 |
Age | 2.27 | 1 | 0.132 | nd | nd | 0.180 |